Phase III Study of Rituximab (Genetical Recombination) for the Treatment for Idiopathic Membranous Nephropathy With Nephrotic Syndrome
Conditions: Glomerulonephritis, Membranous; Nephrotic Syndrome,Idiopathic Interventions: Drug: Rituximab (genetical recombination); Drug: Placebo Sponsor: Shoichi Maruyama MD PhD Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials